Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 16Rectal Neoplasms 4Colonic Neoplasms 4Stomach Neoplasms 3Neoplasm Metastasis 3Neoplasms 2Biliary Tract Neoplasms 2Sarcoma, Ewing 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Metastatic Gastric Adenocarcinoma 1Lung Neoplasms 1Head and Neck Neoplasms 1Gastric Cancer Adenocarcinoma Metastatic 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Dihydropyrimidine Dehydrogenase Deficiency 1Desmoid Tumors 1Craniopharyngioma 1Colorectal Cancer Metastatic 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Advanced/Metastatic Solid Tumors 1Advanced Solid Tumors 1Adenomatous Polyposis Coli 1Adenocarcinoma Of Esophagus 1

Interventions

trifluridine tipiracil drug combination 1tipiracil 1irinotecan sucrosofate 1Trifluridine 1Ramucirumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Metastatic Gastric Adenocarcinoma × trifluridine tipiracil drug combination × Clear all
NCT05927857 2026-04-09

Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .

National Health Research Institutes, Taiwan

Phase 1/2 Recruiting
45 enrolled
Gastrointestinal

Metastatic Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡